167 related articles for article (PubMed ID: 26191276)
1. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
2. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
Rambau PF; Vierkant RA; Intermaggio MP; Kelemen LE; Goodman MT; Herpel E; Pharoah PD; Kommoss S; Jimenez-Linan M; Karlan BY; Gentry-Maharaj A; Menon U; Polo SH; Candido Dos Reis FJ; Doherty JA; Gayther SA; Sharma R; Larson MC; Harnett PR; Hatfield E; de Andrade JM; Nelson GS; Steed H; Schildkraut JM; Carney ME; Høgdall E; Whittemore AS; Widschwendter M; Kennedy CJ; Wang F; Wang Q; Wang C; Armasu SM; Daley F; Coulson P; Jones ME; Anglesio MS; Chow C; de Fazio A; García-Closas M; Brucker SY; Cybulski C; Harris HR; Hartkopf AD; Huzarski T; Jensen A; Lubiński J; Oszurek O; Benitez J; Mina F; Staebler A; Taran FA; Pasternak J; Talhouk A; Rossing MA; Hendley J; ; Edwards RP; Fereday S; Modugno F; Ness RB; Sieh W; El-Bahrawy MA; Winham SJ; Lester J; Kjaer SK; Gronwald J; Sinn P; Fasching PA; Chang-Claude J; Moysich KB; Bowtell DD; Hernandez BY; Luk H; Behrens S; Shah M; Jung A; Ghatage P; Alsop J; Alsop K; García-Donas J; Thompson PJ; Swerdlow AJ; Karpinskyj C; Cazorla-Jiménez A; García MJ; Deen S; Wilkens LR; Palacios J; Berchuck A; Koziak JM; Brenton JD; Cook LS; Goode EL; Huntsman DG; Ramus SJ; Köbel M
J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
[TBL] [Abstract][Full Text] [Related]
3. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.
Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
Cancer Immunol Immunother; 2012 Aug; 61(8):1243-53. PubMed ID: 22258792
[TBL] [Abstract][Full Text] [Related]
4. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
[TBL] [Abstract][Full Text] [Related]
5. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.
Zhang M; He Y; Sun X; Li Q; Wang W; Zhao A; Di W
J Ovarian Res; 2014 Feb; 7():19. PubMed ID: 24507759
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
[TBL] [Abstract][Full Text] [Related]
7. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.
Beeghly-Fadiel A; Wilson AJ; Keene S; El Ramahi M; Xu S; Marnett LJ; Fadare O; Crispens MA; Khabele D
J Ovarian Res; 2018 Feb; 11(1):17. PubMed ID: 29482584
[TBL] [Abstract][Full Text] [Related]
8. High Expression of NRF2 and Low Expression of KEAP1 Predict Worse Survival in Patients With Operable Triple-Negative Breast Cancer.
Lee YS; Kang J; Jung ES; Lee A
J Breast Cancer; 2023 Oct; 26(5):461-478. PubMed ID: 37926068
[TBL] [Abstract][Full Text] [Related]
9. SSRI use and clinical outcomes in epithelial ovarian cancer.
Christensen DK; Armaiz-Pena GN; Ramirez E; Matsuo K; Zimmerman B; Zand B; Shinn E; Goodheart MJ; Bender D; Thaker PH; Ahmed A; Penedo FJ; DeGeest K; Mendez L; Domann F; Sood AK; Lutgendorf SK
Oncotarget; 2016 May; 7(22):33179-91. PubMed ID: 27121207
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.
Cho H; Hur HW; Kim SW; Kim SH; Kim JH; Kim YT; Lee K
Cancer Immunol Immunother; 2009 Jan; 58(1):15-23. PubMed ID: 18414853
[TBL] [Abstract][Full Text] [Related]
11. Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma.
Skirnisdottir I; Seidal T; Åkerud H
Int J Gynecol Cancer; 2015 Sep; 25(7):1239-47. PubMed ID: 26035126
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.
Dong S; Yu F; Liu Y; Yu X; Sun X; Wang W; Wang Y
Ginekol Pol; 2023; 94(10):792-798. PubMed ID: 36477777
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic Impact of NANOG, ZEB1, and EpCAM Biomarkers on Prognosis of Serous Ovarian Carcinoma.
Ibrahim HM; Abdelrahman AE; Elsebai E; Gharieb SA; Fahmy MM; Ramadan MSH; Wasfy MA; Abdullatif A
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3247-3259. PubMed ID: 37774079
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database.
Yang SP; Su HL; Chen XB; Hua L; Chen JX; Hu M; Lei J; Wu SG; Zhou J
JMIR Public Health Surveill; 2021 Nov; 7(11):e25976. PubMed ID: 34787583
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer.
Nwachukwu CR; Harris JP; Chin A; Von Eyben R; Giaretta S; Shaffer JL; Hiniker SM; Kapp DS; Folkins AK; Kidd EA
Int J Gynecol Pathol; 2019 Nov; 38(6):588-596. PubMed ID: 31593028
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
Martins FC; Couturier DL; Paterson A; Karnezis AN; Chow C; Nazeran TM; Odunsi A; Gentry-Maharaj A; Vrvilo A; Hein A; Talhouk A; Osorio A; Hartkopf AD; Brooks-Wilson A; DeFazio A; Fischer A; Hartmann A; Hernandez BY; McCauley BM; Karpinskyj C; de Sousa CB; Høgdall C; Tiezzi DG; Herpel E; Taran FA; Modugno F; Keeney G; Nelson G; Steed H; Song H; Luk H; Benitez J; Alsop J; Koziak JM; Lester J; Rothstein JH; de Andrade JM; Lundvall L; Paz-Ares L; Robles-Díaz L; Wilkens LR; Garcia MJ; Intermaggio MP; Alcaraz ML; Brett MA; Beckmann MW; Jimenez-Linan M; Anglesio M; Carney ME; Schneider M; Traficante N; Pejovic N; Singh N; Le N; Sinn P; Ghatage P; Erber R; Edwards R; Vierkant R; Ness RB; Leung S; Orsulic S; Brucker SY; Kaufmann SH; Fereday S; Gayther S; Winham SJ; Kommoss S; Pejovic T; Longacre TA; McGuire V; Rhenius V; Sieh W; Shvetsov YB; Whittemore AS; Staebler A; Karlan BY; Rodriguez-Antona C; Bowtell DD; Goode EL; Høgdall E; Candido Dos Reis FJ; Gronwald J; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; Fasching PA; Crawford R; Deen S; Menon U; Huntsman DG; Köbel M; Ramus SJ; Pharoah PDP; Brenton JD
Br J Cancer; 2020 Sep; 123(5):793-802. PubMed ID: 32555365
[TBL] [Abstract][Full Text] [Related]
17. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.
Lim A; Mesher D; Gentry-Maharaj A; Balogun N; Widschwendter M; Jacobs I; Sasieni P; Menon U
BJOG; 2016 May; 123(6):1012-20. PubMed ID: 26032603
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.
Sorbye SW; Kilvaer TK; Valkov A; Donnem T; Smeland E; Al-Shibli K; Bremnes RM; Busund LT
PLoS One; 2012; 7(10):e47068. PubMed ID: 23071715
[TBL] [Abstract][Full Text] [Related]
19. KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer.
Zhao H; Guo E; Hu T; Sun Q; Wu J; Lin X; Luo D; Sun C; Wang C; Zhou B; Li N; Xia M; Lu H; Meng L; Xu X; Hu J; Ma D; Chen G; Zhu T
Oncotarget; 2016 Jul; 7(28):43924-43938. PubMed ID: 27270322
[TBL] [Abstract][Full Text] [Related]
20. Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer.
Liang J; Yang B; Cao Q; Wu X
Gynecol Obstet Invest; 2016; 81(6):529-536. PubMed ID: 27160772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
